Akebia Ther

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients, and Auryxia, a ferric citrate used to control serum phosphorus levels in adult patients with DD-CKD and to treat iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 in Phase 2 clinical trials for cardiac surgery-related acute kidney injury and acute respiratory distress syndrome, and AKB-10108 for retinopathy of prematurity in neonates. Akebia has license and collaboration agreements with Tanabe Pharma Corporation for Vafseo in Japan and other Asian countries, as well as agreements with CSL Vifor, Averoa, Panion & BF Biotech, Cyclerion Therapeutics, and Q32. Incorporated in 2007, the company is headquartered in Cambridge, Massachusetts.

AKBA

Akebia Therapeutics grants inducement stock options to three new employees

Akebia Therapeutics granted three newly hired employees options to purchase an aggregate of 125,600 shares of common stock on June 30, 2026, as an inducement material to their employment. The options have an exercise price of $1.14 per share, equal to the closing price on the grant date, and vest over four years with 25% after one year and the remainder quarterly thereafter. Each option has a 10-year term and was granted under Nasdaq Listing Rule 5635(c)(4).

AKBA

GlobeNewswire·78dRead more →

AKBA▲

Akebia Therapeutics Strengthens Vafseo Patent Protection Through 2036

Akebia Therapeutics has strengthened the intellectual property protection for its flagship therapy Vafseo, receiving a new patent listing in the FDA's Orange Book and notification of eligibility for a five-year extension of a composition of matter patent. The additions bring the company's Orange Book-listed patents covering Vafseo to 14, with protection now extending through 2036. The company reported first-quarter 2026 Vafseo net product revenue of $15.8 million, with patient numbers up approximately 60% from the prior quarter and around 1,025 prescribers, a 28% increase from Q4 2025. Total first-quarter revenue was $53.5 million, compared with $57.3 million in the same period last year, and cash resources stood at approximately $162.6 million as of March 31, 2026.

AKBA ▲

Insider Monkey·80dRead more →